In HCV-induced vasculitis patients, “ultra-low” doses of IL-2 induced expansion of CD4+CD25+FOXP3+ Tregs, while effector T-cells appeared relatively unaffected, encouraging the use of IL-2 as a therapeutic strategy in other vasculitides (123). This evidence concerns the gene IL2 and vasculitis.